Latest Articles
- Where to draw the line using statins: Lessons from 4S to AFCAPS/TexCAPS
For patients at low risk, a treatment that is beneficial statistically may not be practical or economical. But how should this question be decided? And who should decide?
- In preventive cardiology there is no ‘One True Thing’
In preventing coronary artery disease, the only approach that works is multifactorial, focusing on permanent changes in diet, exercise, and stress management.
Should everyone over age 75 take a multivitamin?Many—perhaps most—seniors are at risk of malnutrition, but age should not be the sole criterion.
- Eradicating H pylori in nonulcer dyspepsia: 7 reasons for vs 7 reasons against
A spirited debate between two experts on a contentious topic.
- Antiviral agents for treating influenza
We now have four antiviral drugs for treating influenza. Who should receive them? Which one to use?
- The spectrum of nonalcoholic fatty liver disease: From steatosis to nonalcoholic steatohepatitis
This recently discovered disease is a common cause of elevated liver enzymes. We are beginning to understand which patients are at greatest risk of progressive liver disease.
- Is there an advantage to combination therapy with ACE inhibitors and angiotensin II-receptor blockers?
Theoretic reasons and small studies suggest the two types of drugs may be useful in combination, but a definitive answer awaits the results of larger studies.
- Psoriasis: A clinical update on diagnosis and new therapies
A framework for recognizing the many forms of psoriasis and a logical approach to therapy, which now includes, in severe cases, powerful immunosuppressive drugs.
- Glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes
These potent antiplatelet agents constitute a breakthrough, hut questions remain about their safety, cost-effectiveness, and proper empiric use. With an illustration explaining the paradoxical prothrombotic effect of fibrinolytic drugs.
